Vadadustat

About Akebia Therapeutics

Founded in 2007, Akebia Therapeutics has established itself as a leader in the renal community, dedicated to bettering the lives of those impacted by kidney disease. The company has built a fully integrated organization with a nephrology-focused commercial team and a robust R&D engine centered on oral HIF-PH inhibitors. With two FDA-approved products and a late-stage candidate, vadadustat, in development for anemia due to chronic kidney disease, Akebia aims to address significant unmet needs and set new standards of care.

Therapeutic Areas